< Back to previous page
Researcher
Max Mazzone
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Mazzone Max (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 10 of 63
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
21 - 30 of 179
- Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes(2022)
Authors: Max Mazzone, Peter Carmeliet
- Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma Development(2022)
Authors: Max Mazzone
Pages: 609 - 624 - Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer(2022)
Authors: Ward Celus, Silvia Rivis, Ewout Landeloos, Yannick Van Herck, Abhishek Garg, Chris Marine, Mario di Matteo, Oliver Bechter, Max Mazzone
Pages: 126 - 141 - The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis(2022)
Authors: Max Mazzone
- N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages(2021)
Authors: Max Mazzone
- Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function(2021)
Authors: Max Mazzone
Pages: 1071 - 1090 - ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3(2021)
Authors: Federico Virga, Max Mazzone
Pages: 13 - 23 - Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2(2021)
Authors: Max Mazzone
Pages: 1849 - 1861 - Cryptic transcripts: the masked heroes that break tumor immunotolerance and rescue the immunotherapy response(2021)
Authors: Laurien Van Dyck, Diether Lambrechts, Max Mazzone, Bernard Thienpont
- Isolation and separation of murine tumor-associated macrophages (TAMs) subpopulations from orthotopic 4T1 breast tumors(2021)
Authors: Max Mazzone
Patents
1 - 10 of 10
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)
- Biomarker for anti-tumor therapy (Inventor)
- Combination of p2y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Inhibition of slc4a4 in the treatment of cancer (Inventor)
- Means and methods to treat inflammatory diseases (Inventor)
- Glutamine dehydrogenase inhibitors for use in muscle regeneration (Inventor)
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Podoplanin positive macrophages (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)